Loading clinical trials...
Loading clinical trials...
Phase I Study of T Cells Expressing an Anti-CD19 and Anti-CD20 Bispecific Chimeric Receptor in Patients With B Cell Malignancies
Conditions
Interventions
anti-CD19 anti-CD20 Bispecific CAR-T
Locations
1
China
Hebei Yanda Ludaopei Hospital
Sanhe, Hebei, China
Start Date
March 1, 2021
Primary Completion Date
March 1, 2022
Completion Date
March 1, 2023
Last Updated
January 20, 2021
NCT05529069
NCT00106925
NCT06337318
NCT07388563
NCT05139017
NCT06285890
Lead Sponsor
Beijing Doing Biomedical Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions